{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-077074","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2023-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.923854+00:00","generated_at":"2026-06-13T13:40:18.958049+00:00","sec_items":["2.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Marker Therapeutics completes $19M sale of manufacturing facilities to Cell Ready, exits manufacturing operations","bullets":["Completed disposition of manufacturing facilities and equipment to Cell Ready for $19M on June 26, 2023.","Transaction includes assignment of leases and sale of equipment; Cell Ready to offer employment to ~50 Marker employees.","Pro forma results show net loss per share improvement: Q1 2023 by $0.01, FY2022 by $1.18, FY2021 by $2.11.","Pro forma cash and cash equivalents increased to $25.2M from $6.4M as of March 31, 2023.","John Wilson, Marker board member, is CEO and sole member of Cell Ready, creating a related-party transaction."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-077074","json":"https://secwatch.observer/filing/0001104659-23-077074.json","markdown":"https://secwatch.observer/filing/0001104659-23-077074.md","text":"https://secwatch.observer/filing/0001104659-23-077074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923077074/0001104659-23-077074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923077074/tm2319618d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T13:40:18.958049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc8c73c7da0a6f94a82f2d12a96890f0ffc9154f","claim":"Marker Therapeutics, Inc. completed a disposition involving Cell Ready, LLC for approximately $19.0 million (closed 2023-06-26).","evidence_excerpt":"Company completed the disposition of the Purchased Assets to Cell Ready pursuant to the Transaction. The aggregate consideration paid for the Purchased Assets was approximately $19.0 million. In connection with the Transaction, Cell Ready plans to make offers of employment to approximately 50 of the Company's employees currently employed in its manufacturing,","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923077074/0001104659-23-077074-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Cell Ready, LLC"},{"label":"Consideration","value":"approximately $19.0 million"},{"label":"Closing","value":"2023-06-26"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}